Fig. 2: In vitro validation of anti-leukemic compounds from an in silico screen against AML 8227.
From: Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
a Summary of all compounds that affected at least one population in 8227 AML cells. Red denotes decreased viability of at least 50% at the indicated concentration and blue denotes increased viability of at least 50% at the indicated concentration; experiment performed in duplicate. An ‘*’ indicates that the compound was retested. b, c Confirmation of the effect of 9 compounds shown to be preferential for CD34+ cells on b the CD15+ terminally differentiated blast population and c the CD34+ CD38− LSC-containing population. d Viability of bulk and CD34+ CD38− AML 8227 cells treated with the three cardiac glycosides, strophanthidin, digoxin and ouabain at indicated concentrations for 6 days. Data are representative of three independent experiments performed in triplicate and displays the mean ± s.d.
